Researchers at Keck Medicine, University of Southern California (USC) have discovered that combining immunotherapy with laser heat therapy could significantly extend the survival of individuals diagnosed with deadly brain cancers, according to a recent announcement. The findings represent a potential breakthrough for patients with glioblastoma and other aggressive brain tumors that have limited treatment options.
The study, which combined laser interstitial thermal therapy (LITT) with immunotherapy, demonstrated improved outcomes in patients who had previously exhausted standard treatments. LITT uses a laser to heat and destroy tumor tissue, while immunotherapy activates the body's immune system to attack cancer cells. The synergistic effect appears to enhance the immune response against the tumor.
Entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP), which are engaged in developing treatments for brain cancers, may be impacted by these developments. The research highlights the potential of combination therapies in oncology.
This advancement is particularly important because brain tumors are notoriously difficult to treat due to the blood-brain barrier, which prevents many drugs from reaching the brain. The combination of LITT and immunotherapy may help overcome this barrier by temporarily disrupting it with heat, allowing immune cells to access the tumor site.
The study's results offer new hope for patients with limited options, as current treatments for glioblastoma, the most common and aggressive form of brain cancer, have a median survival of only 15 months. The new approach could potentially double or triple survival times in some patients.
Further research and clinical trials are needed to confirm these findings and determine the optimal protocols for using this combination therapy. The researchers at Keck Medicine are continuing to investigate the mechanisms behind the improved survival and are planning larger studies.
For more information about the study and related companies, visit BioMedWire, a platform covering developments in biotechnology and life sciences. BioMedWire is part of the Dynamic Brand Portfolio within the InvestorBrandNetwork (IBN), which provides corporate communications solutions and news distribution.
